PL3496730T3 - Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych - Google Patents

Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych

Info

Publication number
PL3496730T3
PL3496730T3 PL17841210.2T PL17841210T PL3496730T3 PL 3496730 T3 PL3496730 T3 PL 3496730T3 PL 17841210 T PL17841210 T PL 17841210T PL 3496730 T3 PL3496730 T3 PL 3496730T3
Authority
PL
Poland
Prior art keywords
neurological disorders
mesenchymal cell
derived exosomes
treat neurological
treat
Prior art date
Application number
PL17841210.2T
Other languages
English (en)
Polish (pl)
Inventor
Daniel Offen
Nisim PERETS
Original Assignee
Ramot At Tel-Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv University Ltd. filed Critical Ramot At Tel-Aviv University Ltd.
Publication of PL3496730T3 publication Critical patent/PL3496730T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17841210.2T 2016-08-14 2017-08-14 Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych PL3496730T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374852P 2016-08-14 2016-08-14
PCT/IL2017/050899 WO2018033911A1 (en) 2016-08-14 2017-08-14 Mesenchymal cell-derived exosomes to treat neurological disorders

Publications (1)

Publication Number Publication Date
PL3496730T3 true PL3496730T3 (pl) 2022-09-26

Family

ID=61196484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17841210.2T PL3496730T3 (pl) 2016-08-14 2017-08-14 Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych

Country Status (10)

Country Link
US (2) US11129852B2 (cg-RX-API-DMAC7.html)
EP (1) EP3496730B1 (cg-RX-API-DMAC7.html)
JP (1) JP7014449B2 (cg-RX-API-DMAC7.html)
CN (1) CN109843305B (cg-RX-API-DMAC7.html)
AU (1) AU2017311684B2 (cg-RX-API-DMAC7.html)
ES (1) ES2925527T3 (cg-RX-API-DMAC7.html)
IL (1) IL264825B (cg-RX-API-DMAC7.html)
PL (1) PL3496730T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201901272WA (cg-RX-API-DMAC7.html)
WO (1) WO2018033911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
CA3112505C (en) * 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP3990625A4 (en) 2019-06-26 2023-07-19 Technion Research & Development Foundation Limited PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS
JP6830286B1 (ja) 2020-06-26 2021-02-17 デクソンファーマシューティカルズ株式会社 精巣機能改善剤および精巣機能改善方法
US20230210910A1 (en) 2020-07-17 2023-07-06 Dexon Pharmaceuticals Inc. Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device
EP4212163A4 (en) 2020-09-08 2024-09-18 Dexon Pharmaceuticals Inc. CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR
JP6974892B1 (ja) 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 癌悪液質の改善剤および癌悪液質の改善方法
JP7492757B2 (ja) 2022-03-22 2024-05-30 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
US20250136992A1 (en) 2022-05-15 2025-05-01 Nurexone Biologic Ltd. Anti-pten rna interference oligonucleotides and uses thereof
CN115006427A (zh) * 2022-05-31 2022-09-06 尧舜泽生物医药(南京)有限公司 骨髓间充质干细胞外泌体在治疗帕金森病中的应用
EP4541359A1 (en) 2022-06-20 2025-04-23 Dexon Pharmaceuticals Inc. Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease
WO2023248844A1 (ja) 2022-06-20 2023-12-28 Ｄｅｘｏｎファーマシューティカルズ株式会社 Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
CN120078807B (zh) * 2025-02-08 2026-03-31 广东省人民医院 改善卵巢功能的MSC-sEVs药物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20060188496A1 (en) * 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
AU2009203638C1 (en) 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
JPWO2011118795A1 (ja) 2010-03-26 2013-07-04 国立大学法人名古屋大学 損傷部治療用組成物
JP5608927B2 (ja) * 2010-04-13 2014-10-22 国立大学法人名古屋大学 歯髄幹細胞を用いた神経疾患治療用組成物
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
WO2012020308A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
WO2012068170A2 (en) * 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2013124817A2 (en) * 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP2833893B1 (en) 2012-04-03 2018-08-29 Reneuron Limited Stem cell microparticles
WO2013186735A2 (en) 2012-06-14 2013-12-19 Bar-Ilan Research And Development Company Ltd. Photothermal detection
WO2015038075A1 (en) * 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
WO2016149358A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle

Also Published As

Publication number Publication date
EP3496730A1 (en) 2019-06-19
EP3496730B1 (en) 2022-05-25
AU2017311684A2 (en) 2019-03-28
AU2017311684B2 (en) 2023-05-04
SG11201901272WA (en) 2019-03-28
JP7014449B2 (ja) 2022-02-01
AU2017311684A1 (en) 2019-03-07
JP2019524824A (ja) 2019-09-05
IL264825A (cg-RX-API-DMAC7.html) 2019-04-30
EP3496730A4 (en) 2020-05-06
CN109843305B (zh) 2023-03-10
US20210361717A1 (en) 2021-11-25
ES2925527T3 (es) 2022-10-18
CN109843305A (zh) 2019-06-04
US20190209621A1 (en) 2019-07-11
WO2018033911A1 (en) 2018-02-22
US11129852B2 (en) 2021-09-28
CA3033951A1 (en) 2018-02-22
IL264825B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
PL3496730T3 (pl) Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL273693A (en) Treatment of inflammatory disorders
IL259147A (en) Exosomes derived from mesenchymal stem cells and their uses
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
IL262348A (en) Preparations for the treatment of excessive radiation disorders
SG11201701377YA (en) Compositions and methods to treat vision disorders
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
SG11201609993YA (en) Treatment of immune disorders
GB201412578D0 (en) Treatment of neurological diseases
PL3200828T3 (pl) Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych
HUE058308T2 (hu) Vérlemezkepellet-lizátum neurológiai rendellenességek kezelésében való felhasználásra
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
GB201612043D0 (en) Composition for treatment of disorders
ZA201507724B (en) The treatment of inflammatory disorders
LT3458067T (lt) Neurologinių sutrikimų gydymas
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
EP3215178A4 (en) Treatment of cns inflammatory disorders
EP3245215A4 (en) Methods of treating neurological inflammatory disorders
TWI561235B (en) Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
SG11201706952VA (en) Compositions and methods for the treatment of epilepsy and neurological disorders
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders